TVB-2640

Catalog No.S9714 Synonyms: ASC-40, FASN-IN-2

For research use only.

TVB-2640 (ASC-40, FASN-IN-2) is an orally bioavailable, pharmacological fatty acid synthase (FAS/FASN) inhibitor with therapeutic potential in patients with NAFLD and nonalcoholic steatohepatitis.

TVB-2640 Chemical Structure

CAS No. 1399177-37-7

Selleck's TVB-2640 has been cited by 3 Publications

Purity & Quality Control

Choose Selective Fatty Acid Synthase Inhibitors

Biological Activity

Description TVB-2640 (ASC-40, FASN-IN-2) is an orally bioavailable, pharmacological fatty acid synthase (FAS/FASN) inhibitor with therapeutic potential in patients with NAFLD and nonalcoholic steatohepatitis.
Targets
FAS [1]
()

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 88 mg/mL
(200.2 mM)
Ethanol 88 mg/mL
(200.2 mM)
Water Insoluble

Chemical Information

Molecular Weight 439.55
Formula

C27H29N5O

CAS No. 1399177-37-7
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04906421 Recruiting Drug: TVB-2640|Other: Placebo Nonalcoholic Fatty Liver Disease Sagimet Biosciences Inc. August 12 2021 Phase 2
NCT04843449 Completed Drug: ASC40|Drug: Itraconazole|Drug: rifampicin Healthy Ascletis Pharmaceuticals Co. Ltd. April 4 2021 Phase 1
NCT04352361 Completed Drug: TVB-2640|Drug: Placebo Healthy Ascletis Pharmaceuticals Co. Ltd. April 2 2020 Phase 1
NCT03808558 Recruiting Drug: TVB-2640 KRAS Gene Mutation David E Gerber|Sagimet Biosciences Inc.|Cancer Prevention Research Institute of Texas|University of Texas Southwestern Medical Center September 11 2019 Phase 2
NCT03938246 Completed Drug: TVB-2640|Other: Placebo Non-Alcoholic Fatty Liver Disease Sagimet Biosciences Inc. March 22 2019 Phase 2
NCT02980029 Recruiting Drug: TVB-2640|Other: Placebo Colon Cancer Mark Evers|University of Kentucky October 6 2017 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy TVB-2640 | TVB-2640 supplier | purchase TVB-2640 | TVB-2640 cost | TVB-2640 manufacturer | order TVB-2640 | TVB-2640 distributor